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Abstract 
 
With it’s identification as a proto-oncogene in chronic lymphocytic leukemia (CLL) and 
central role in regulating NF-kB signalling, it is perhaps not surprising that there have 
been an increasing number of studies in recent years investigating the role of BCL-3 
(B-Cell Chronic Lymphocytic Leukaemia/Lymphoma 3) in a wide range of human 
cancers. Importantly, this work has begun to shed light on our mechanistic 
understanding of the function of BCL-3 in tumour promotion and progression. Here we 
summarise the current understanding of BCL-3 function in relation to the 
characteristics or traits associated with tumorigenesis, termed “Hallmarks of Cancer”.  
 
With the focus on colorectal cancer (CRC), a major cause of cancer related mortality 
in the UK, we describe the evidence that potentially explains why increased BCL-3 
expression is associated with poor prognosis in CRC. As well as promoting tumour cell 
proliferation, survival, invasion and metastasis, a key emerging function of this proto-
oncogene is the regulation of the tumour response to inflammation. We suggest that 
BCL-3 represents an exciting new route for targeting the Hallmarks of Cancer; in 
particular by limiting the impact of the enabling hallmarks of tumour promoting 
inflammation and cell plasticity. As BCL-3 has been reported to promote the stem-like 
potential of cancer cells, we suggest that targeting BCL-3 could increase the tumour 
response to conventional treatment, reduce the chance of relapse and hence improve 
the prognosis for cancer patients.  
 
 
 
Summary 
 
In recent years there has been an increasing number of studies investigating the role 
of the atypical IκB protein BCL-3 in a wide range of human cancers; here we review 
its function in relation to the “Hallmarks of Cancer”. 
  
Introduction 
 
Globally, cancer is one of the most common causes of mortality, with colorectal cancer 
(CRC) the third most common malignancy and fourth highest cause of cancer death 
(1). Tumorigenesis is driven through acquisition of somatic mutations, epigenetic 
modifications (such as alterations in alternative splicing) and regulation by non-coding 
RNA molecules that function to regulate the expression of tumour suppressor and 
oncogenes. These changes lead to phenotypic alterations that mark the transformation 
of normal cells to cancer cells, known as the ‘Hallmarks of Cancer’, as originally 
defined by Hanahan and Weinberg (2). These Hallmarks are evading apoptosis, self-
sufficiency in growth signals, insensitivity to anti-growth signals, limitless replicative 
potential, sustained angiogenesis and tissue invasion and metastasis. An updated 
version of the hallmarks describe a further two ‘emerging hallmarks’; deregulating 
cellular energetics and avoiding immune destruction, along with two ‘enabling 
characteristics’; genome instability and tumour promoting inflammation (3).  
 
NF-κB is a critical inflammatory signalling pathway  
The NF-κB family of transcription factors is quickly activated following numerous stress 
stimuli including infection (4), ionizing radiation (5), chemical/physical stress and 
proinflammatory signals - including those related to cancer (6, 7). NF-κB signalling 
relies on three principal protein families; NF-κB proteins, inhibitor of kappa B (IκB) 
proteins and the IKK complex (Figure 1). NF-κB proteins are a group of structurally-
related subunits; RelA (p65), RelB, c-Rel, NF-κB1 (p105/p50) and NF-κB2 (p100/p52) 
(8, 9). All NF-κB subunits contain an N-terminal Rel homology domain (RHD), which 
mediates DNA binding, dimerisation of subunits and inhibitory protein binding (10). 
P65, RelB and c-Rel possess a transactivation domain (TAD) which enables 
transcriptional activation following stimulus. Dimerisation of NF-κB subunits into homo- 
or hetero-dimers follows activation through either the canonical or non-canonical 
pathways, although this is perhaps an oversimplification as up to 15 different NF-κB 
family complexes can be formed (11, 12). The canonical and non-canonical signalling 
pathways have been the subject of many elegant reviews and are not covered here.  
 
The term “atypical NF-B pathway” involves NF-B dimers and their associated 
activation that do not fall under the umbrella of the canonical or non-canonical 
pathways: included in this atypical calssification are the p50/p52 homodimers and their 
associated co-regulatory protein, BCL-3, which will be the focus of this review. This 
pathway is a critical component of the broader NF-B response and plays a role in 
fine-tuning the canonical and non-canonical responses to an inflammatory stimulus. 
However, it is important to point out that BCL-3 may elicit functional effects through all 
branches of NF-B signaling due to its various nuclear and cytoplasmic roles, as 
explored throughout this review. 
 
BCL-3  
The BCL-3 gene was first found in chronic lymphocytic leukaemia after sequencing of 
recurring t(14;19)(q32.3;q13.1) translocations which result in transcriptional 
upregulation of BCL3 (13). This revealed a protein with 7 ankyrin repeat domains, a 
proline rich N terminal domain and a serine and proline-rich C-terminal domain with a 
total molecular weight of around 47 kDa (14). Studies in normal blood cells showed 
increased expression of BCL-3 following mitogenic stimulation and also linked the 
structure of BCL-3 to those of known cell cycle regulators, prompting the authors to 
label it as a candidate proto-oncogene (14). Shortly after its discovery, a flurry of 
papers from multiple groups linked BCL-3 to the NF-κB signalling pathway (15-18) and 
BCL-3 was subsequently classified as an atypical member of the IκB family due to its 
contrasting roles in NF-κB-mediated transcription. 
 
BCL-3 as a regulator of an atypical NF-κB signalling pathway 
Functionally, BCL-3 differs from the other IκB proteins (IκB-α, IκB-β and IκB-ε) which 
bind to NF-κB proteins in the cytoplasm, inhibiting their nuclear translocation and 
subsequent transcriptional activity. In both non-tumour and tumour cells, BCL-3 binds 
to processed p50 and p52 homodimers to activate or repress a subset of NF-κB 
regulated genes (Figure 2). P50 and p52 are thought to form strong homodimers with 
high affinity compared to other homodimer species (19). These homodimers bind to 
the majority of κB sites at gene promoter regions and binding is known to occur at 
multiple sites within the same promoter (20). In contrast to other NF-κB subunits, p50 
and p52 lack TADs and subsequently require cofactors to induce activation of 
transcription (21). First thought to inhibit nuclear translocation of p50 homodimers (22), 
binding of BCL-3 to p50 homodimers was later shown to unmask the NLS of p50 
allowing translocation of the complex into the nucleus (23, 24).  
 
Trans-activator or trans-repressor 
There have been many studies investigating the role of BCL-3 in the regulation of NF-
κB target genes. Interestingly, BCL-3 has been demonstrated to both activate and 
repress transcription of NF-κB targets in a context-dependent manner with respect to 
the promoter, cell type or stimuli analysed. In terms of transcriptional repression, early 
work from Kerr et al. described inhibition of NF-κB reporter activity in the presence of 
BCL-3 in drosophila S2 cells and Jurkat T-cells (18). In support of this, using cells from 
Bcl3-/- mice it was demonstrated that Bcl-3 could enhance repression of NF-κB target 
genes. This was shown to be through inhibition of ubiquitination and subsequent 
proteolytic degradation of p50 homodimers bound to κB sites at promoters of certain 
genes; thus, extending the half-life of repressive p50 homodimers (25, 26). In addition, 
BCL-3 can recruit co-repressors CtBP and HDAC3 to repress transcription of NF-κB 
target genes in transformed keratinocytes (27). Therefore, BCL-3 can repress 
transcription by stabilising repressive p50 homodimers or via recruitment of co-
repressors. 
 
Conversely, BCL-3 may activate transcription using a number of different mechanisms. 
Franzoso et al. demonstrated an interaction between BCL-3 and p50 and observed an 
increase in NF-κB reporter activity through BCL-3-mediated reversal of p50 
homodimer-induced repression in transfected NTERA2 cells (17). A further 
mechanism of transcriptional activation by BCL-3 is the direct removal of repressive 
p50 homodimers already situated at κB sites on DNA, allowing NF-κB subunits 
associated with canonical signalling to bind and activate transcription at these sites 
(17, 28). As an alternative to reversing repression at κB sites, BCL-3 may also directly 
transactivate genes in multiple cell types when associated with p50 or p52 
homodimers; owing to BCL-3 possessing both N- and C- terminal transactivation 
domains (14, 29, 30). 
 
Interaction of BCL-3 with co-regulatory proteins 
BCL-3 can recruit other co-regulators to influence gene expression, as reported by 
Dechend et al. who discovered interactions between BCL-3 and Pirin, Tip60, Jab1 and 
Bard1. Of these interactors, Tip60 and Jab1 were found to enhance transcription of 
the P-selectin promoter in drosophila SL2 cells when co-transfected with Bcl-3 and p50 
(31). This adds a further dimension to the regulation of transcription by BCL-3, with 
some co-regulators resulting in repression of target genes and others in 
transactivation. Further protein-protein interactions have been documented such as 
with Hsp70, HDAC1 and 3, CtBP1 and CtBP2 (27, 32) and more recently β-catenin in 
colorectal cancer cells (33).  
 
Acetylation is known to play an important role in NF-κB family subunits (34), although 
it is unknown if the bridging role that BCL-3 plays with proteins such as Tip60 and 
HDAC1/3 facilitates acetylation of p50 or p52 homodimers. Evidence exists to show 
that p50 can be acetylated and that this acetylation results in enhanced binding to κB 
sites in T-cells (35), it is interesting to speculate that Tip60 and HDAC1/3 interactions 
could be influential in determining homodimer transactivation activity in the nucleus.  
 
Although early work on BCL-3 focused on its transcriptional regulation in relation to its 
interaction with NF-κB homodimeric subunits, more recent work has centred on how 
post-translational modifications affect these interactions and downstream 
transcriptional regulation (Figure 3 summarises the key modifications of BCL-3). BCL-
3 is extensively phosphorylated at its C-terminus, which regulates p52 (36) and p50 
(24, 37) homodimer binding. In NIH3T3 cells, Viatour et al. demonstrated 
phosphorylation of BCL-3 at residues S394 and S398 by glycogen synthase kinase 3 
promoted proteasomal degradation of BCL-3 (38). A recent mass spectrometry study 
in HEK293T cells has revealed 27 phosphorylation sites on BCL-3 (39). Subsequent 
characterization revealed phosphorylation at S33 by Akt shifts polyubiquitination from 
K48 to K63, resulting in resistance to degradation, translocation to the nucleus and 
activation of p52 homodimers (39). S446 phosphorylation by IKK1/2 and S114 
phosphorylation by Erk2 both stabilized the BCL3:p52 complex on DNA to enhance 
transcriptional activation (39). Therefore, whether BCL-3 acts as a co-activator or co-
repressor may be determined by the combination of post-translational modifications - 
brought about by the particular cell type or stimuli - that alter the function and/or 
localisation of BCL-3.  
 
In summary, BCL-3 has multiple functions ranging from activation of p50/p52 subunits 
in the cytoplasm, their nuclear import and modulation of homodimer transactivation 
through facilitating binding of different transcriptional co-regulators. It is also suggested 
that BCL-3 has contrasting functions depending on the pathological model used; in 
particular there is a significant reversal of function in inflammation models (40) which 
could be explained by the availability of co-factors and/or post translational 
modification of chromatin surrounding NF-κB dimers (41).  
 
BCL-3 and Cancer 
Given its identification as a proto-oncogene in CLL and central role in regulating NF-
kB signalling, it is perhaps not surprising that there have been an increasing number 
of studies in recent years investigating the role of BCL-3 in a variety of human solid 
cancers (42). There are multiple post translational modifications that affect the function 
or localization of BCL-3, as discussed above, and may promote the oncogenic 
potential of BCL-3..  
 The clinical utility of BCL-3 as a marker of prognosis is highlighted by a growing 
number of clinical studies: increased protein and mRNA expression has been 
associated with adverse clinicopathological characteristics in Hepatocellular 
carcinoma patients (43). Increased BCL-3 expression was also correlated with adverse 
prognostic features and reduced survival rate in cervical cancer (44). Niu et al. suggest 
that BCL3 is a promising molecular biomarker of pediatric acute myeloid leukemia with 
unfavorable prognosis (45), and the use of BCL-3 expression levels has also been 
proposed to predict response to alkylating agents in glioma (46). Interestingly, BCL-3 
is part of a four gene signature suggested for use in determining the prognosis of 
patients with clear-cell renal-cell carcinoma (47). These and other studies have begun 
to shed light on our mechanistic understanding of the function of BCL-3 in tumour 
promotion and progression, including the role BCL-3 plays in a number of the 
Hallmarks of Cancer (3), as discussed below.  
 
Sustaining proliferative signalling 
Cancer cells can disregard the homeostatic cues that govern normal cells ability to 
grow and, importantly, stop growing. Cancers acquire the ability for self-sustaining 
proliferation through a number of different means, including dysregulation of cell-cycle, 
increased growth factor production, stimulation of cells within the microenvironment 
(resulting in increased pro-proliferative paracrine signalling) and the deregulation of 
growth factor receptors leading to hypersensitivity to growth factors (3, 48). The effect 
of BCL-3 on tumour growth/proliferation has been observed in different tumour types. 
In colorectal cancer cells, BCL-3 induces the post-translational stabilisation of c-MYC 
(mediated by ERK1/2) increasing tumour xenograft size (49); while BCL-3 over 
expression was shown to induce cell cycle progression, mediated by Cyclin D1 in 
hepatocellular carcinoma (43, 50), malignant melanoma (51) and breast cancer (52). 
The converse was also true, as repression of Cyclin D1 by p53 was shown to be 
dependent on BCL-3 suppression in H1229 lung cancer and U2-01 sarcoma cell lines 
(53). Furthermore, proliferation of skin cancer cells was abrogated when nuclear 
translocation of BCL-3 was blocked by its upstream regulator, CYLD (54). 
 
Activating invasion and metastasis 
Invasion into surrounding tissues is a defining feature of malignant cells followed by 
metastasis to distant organ sites, which is often the fatal event of solid malignancy (3). 
In breast cancer models it has been demonstrated that BCL-3 drives metastasis of 
tumour cells (55, 56): In HER2 positive breast tumour cells, BCL-3 knockout (KO) 
resulted in an 80% reduction of metastatic burden in mice following tail-vein injection 
of tumour cells (55). While in the MMTV-PyMT mouse model of mammary 
adenocarcinoma, Bcl-3 suppression using Dox-inducible shRNA resulted in reduction 
of lung metastases, through targeting Smad3 stability in the TGF- signalling pathway 
(56). Additionally, a clinical study examined immunohistochemistry from paired normal 
and tumour tissue in hepatocellular carcinoma and discovered BCL-3 expression 
resulted in advanced TNM stage; this was shown to have contributed to the poorer 
prognosis observed in these patients (43).  
 
Evasion of Apoptosis 
BCL-3 regulates cellular apoptosis in a variety of models. For example, data has 
shown BCL-3 regulates apoptosis in colorectal and cervical tumour cell lines following 
UV-radiation (57) and protects breast carcinoma cells from undergoing apoptosis 
following UV-radiation (58). BCL-3 is thought to inhibit proteins such as Smac/Diabolo 
and p53 through upregulation of HDM2 (59-62). However, even in p53-null 
backgrounds BCL-3 suppression was able to initiate apoptosis through targeting the 
expression of DNA-PKcs (59). BCL-3 is a potent survival factor in colorectal cancer 
(63, 64), and activates the pro-survival AKT/PKB pathway (64). In hepatocellular 
carcinomas, BCL-3 is frequently overexpressed in tumour tissue compared to normal 
tissue, in conjunction with p50 and p52 NF-κB subunits (65). However, recently 
published data using a hepatocyte-specific BCL-3 overexpression mouse model 
revealed that BCL-3 expression promoted hepatocyte death following an inflammatory 
insult. As a result, these mice developed fewer hepatocellular carcinomas (66). This 
study also highlighted that BCL-3 overexpression reduced the influx of certain 
populations of immune cells into the liver (CD8+ T cells, B cells and leukocytes), 
protecting against induced inflammation. It may be that hepatocellular carcinomas are 
particularly sensitive to alterations in canonical NF-κB signalling and that repression of 
canonical NF-κB occurs when BCL-3 is overexpressed in combination with atypical 
NF-κB homodimers, leading to abrogation of apoptosis in this context (26). 
Interestingly, a recent study by Zou et al. described BCL-3-mediated increase in 
checkpoint marker PD-L1 expression, enhancing proliferation of ovarian cancer cells 
(67). PD-L1 is known to inhibit tumour ifiltrating lymphocytes (68); therefore, it is 
tempting to speculate that BCL-3 could play a similar role in protecting against tumour 
cell apoptosis via regulation of tumour infiltrating lymphocytes in both hepatocellular 
carcinoma and ovarian cancer. 
 
The role of BCL-3 in inflammation and immunity 
NF-κB signalling is recognised to have contrasting function depending on the biological 
context (69), consistent with the role of BCL-3 in cancer compared to its role in non-
malignant, inflammatory models. Interestingly, the presence of BCL-3 appears to 
attenuate inflammation in non-malignant models. BCL-3 KO mice have defects in 
lymphoid organs, including aberrant development of Peyer’s patches, which would 
affect intestinal immune surveillance and response to certain pathogens (70). 
 
Effects of BCL-3 KO have been studied in a variety of different inflammatory models, 
including pancreatitis, colitis, dermatitis and rheumatoid arthritis (RA). In a mouse 
model of acute pancreatitis, where pancreatic inflammation is stimulated using cerulin 
or sodium taurocholate, results showed that Bcl-3-/- mice had increased levels of 
oedema and necrosis in their pancreata (71). The observation that Bcl-3 KO increases 
the severity of inflammation has been corroborated in an inflammatory bowel disease 
model (IBD; Crohn’s disease and ulcerative colitis) (40). In a contact hypersensitivity 
model of atopic dermatitis, Bcl-3-/- mice had worsened inflammation following topical 
oxalazone treatment, which appeared to be mediated through increased cytokine 
production (72). Earlier evidence for this mechanism came from Carmody et al. via 
examining the expression of pro-inflammatory cytokines in murine immune cells 
(macrophages and dendritic cells) devoid of BCL-3 (26). BCL-3 acted to repress 
canonical NF-κB transcription of target cytokines (such as TNF-, CXCL1, CXCL2, IL-
1 and IL-10), leading to significantly increased expression following inflammatory 
stimuli in the Bcl-3 KO cells, corroborating previous data (73). This study was 
particularly interesting as it demonstrated that not all cytokines responded in the same 
way to Bcl-3 KO. For cytokines that showed an early spike in transcription following 
lipopolysaccharide (LPS), Bcl-3 KO had a significant impact on their production; while 
cytokines such as IL-6 showed a slower increase in transcription that was unchanged 
in Bcl-3-/- cells compared to Bcl-3 WT controls. These data suggest that Bcl-3 KO 
affects different aspects (early and late) of the NF-κB-driven response to inflammation. 
Interestingly, IKK KO in intestinal epithelial cells worsens the histological severity of 
colonic inflammation and led to the animals losing greater amounts of weight (74). If 
Bcl-3 knockout leads to increased binding of canonical NF-κB dimers (26), then it is 
unclear why the phenotype observed with Bcl-3 knockout is similar to the phenotype 
observed when canonical NF-κB has been inactivated by IKK deletion. It may be that 
long term knockout and transient knockdown have different effects on the canonical 
(transiently activated) and non-canonical pathway (sustained activation). Additionally, 
the various models and cell types used in these studies may account for some of the 
context-dependent function of Bcl-3. 
 
As a further illustration of the potential context dependent function of BCL-3, another 
recent study showed that Bcl-3 over-expression, specifically in CD4+ T-cells (including 
T regulatory cells), results in a pancolitis of the large bowel of mice (75, 76). This cell-
type specific effect was corroborated by work in CD4+ cells using a rheumatoid arthritis 
(RA) model, which showed over-expression of Bcl-3 in these cells was implicated in 
the pathogenesis of RA (77). Interestingly, Bcl-3-/- T cells failed to induce colitis when 
transferred into Rag1-/- mice (78), suggesting an inability of Bcl-3-/- T cells to respond 
to the microbiota-derived and antigen-specific signals that drive colitis in this model. 
 
Following induction of inflammation there is a concomitant induction of BCL-3 in a 
variety of tissue types. Induction of BCL-3 in response to canonical NF- κB signalling 
was first observed by Brasier et al.  in a hepatocellular carcinoma background (79). 
More recent work has shown the importance of the alternative NF- κB pathway in 
regulation of BCL-3 transctiption in colorectal cancer (63). This is likely to represent a 
feedback loop, in place to regulate pathways such as NF-κB and modulate their 
function following a stimulus. Evidence for this comes from a number of sources; in 
respiratory syncytial virus (RSV) infection of airway epithelial cells, BCL-3 is initially 
upregulated leading to inhibition of NF-κB and STAT transcription by acting as a 
bridging factor to HDAC1, which is transcriptionally repressive (32). Furthermore, BCL-
3 represses STAT3 regulating proteins (80); repression of STAP2 by BCL-3 and p50 
homodimers in conjunction with CtBP on the STAP2 promoter can diminish STAP2 
dependent BRK kinase signalling that phosphorylates and activates STAT3 (81).  BCL-
3 is upregulated in tissue from patients with IBD (75), although further data from IBD 
patients has shown that CpG sites in the BCL3 gene are commonly methylated and 
therefore repressed in B cells isolated from diseased tissue (82). Bcl-3-/- granulocytes, 
isolated following pulmonary transplant in mice, had higher levels of apoptosis as 
measured by annexin V (83). This links to other data showing Bcl-3 KO cells in mice 
colons displayed increased caspase-3 cleavage following dextran-sodium sulphate 
(DSS)-induced colitis (40), suggesting these cells were undergoing more apoptosis. 
Despite these data showing the role of BCL-3 as both a pro-inflammatory and an anti-
inflammatory mediator in non-cancer tissue, it does still appear that BCL-3 has similar 
control over regulation of apoptosis in non-malignant tissue compared to the role of 
BCL-3 in cancers.  
 
In summary, BCL-3 has alternative roles in inflammation depending on the cell type it 
is expressed in and whether all tissues have lost or gained expression. It is suggested 
that KO of Bcl-3 reduces the ability of cells to upregulate survival programmes following 
an inflammatory insult, leading to concomitant rise in apoptosis. This results in a worse 
grade of histological inflammation and tissue damage, thereby propagating  
inflammation. This indicates that it may be the pro-survival role of BCL-3 following 
stress or insult which is critical to its function. 
 
BCL-3 in colorectal cancer  
Importantly, BCL-3 has been shown to play multiple roles in the promotion of colorectal 
cancer. It was discovered by Puvvada et al. that BCL-3 nuclear expression in primary 
tumours was negatively associated with survival. This was calculated through analysis 
of staining and microarray data gathered from tumour specimens of 23 patients that 
had undergone CRC resection (84). Strong nuclear BCL-3 staining was also reported 
in 33% of 270 tumour samples, and was suggested to be an important diagnostic 
determinant (85). These findings were recently corroborated by Legge et al. who (using 
publically available datasets) also reported that BCL-3 expression is associated with 
poor prognosis in colorectal cancer (33). Various mechanisms of BCL-3-mediated 
tumour promotion have been observed in colorectal cancer. One of these is suggested 
to be through regulation of Cyclin D1 in SW480 cells, after it was observed that 
expression of BCL-3 and Cyclin D1 was reduced following treatment with COX-2 
inhibitor NS398 (86). Work from our group has shown that BCL-3 promotes colorectal 
tumour cell survival and growth in vivo, through activation of the AKT pathway via PI3K 
and mTOR signalling (64). Moreover, BCL-3 also stabilises c-MYC—one of the key 
oncogenes in early stage colorectal tumorigenesis following APC inactivation—via 
ERK signaling (49). 
Conversely, a recent paper has suggested Bcl-3 may play a protective role in colitis-
associated colorectal cancers. This observation was made in the mouse model of 
colitis associated colorectal cancers, where tumours are induced through the addition 
of AOM/DSS. Tang et al. demonstrated that mice with conditional deletion of Bcl-3 in 
the intestine developed significantly more polyps than wild type controls, though 
interestingly polyps from both animals were the same size and staining of proliferation 
markers were comparable, indicating Bcl-3 loss was promoting tumour initiating 
capacity. This was suggested to be mediated through TNF-α, as tumour burden was 
not increased in Bcl-3/TNF-α double knockout mice (87). Interestingly, earlier work by 
O’Carroll et al. revealed increased proliferation of intestinal epithelium in Bcl-3-/- mice 
compared to controls, showing that this preserved intestinal tissue architecture, 
protecting against colitis (40). It is tempting to speculate that the increased proliferation 
in Bcl-3-/- intestines following DSS-administration may contribute to tumour 
development observed in the Tang et al. study. It is important to remember that in the 
O’Carroll study, germline Bcl-3 knockout will affect the immune cell compartment which 
will play a key role in colitis associated colorectal cancers, as discussed in the previous 
section. 
 
BCL-3 and colorectal cancer stem cells 
Cancers are thought to arise from stem (or stem-like) cells that gain a competitive 
advantage over their neighbours. With time this clonal expansion of mutant cells will 
eventually give rise to a tumour (88). The cancer stem cell hypothesis states there are 
cells within tumours capable of self-renewal, in addition to producing other 
heterogeneous, differentiated cell types that constitute the tumour mass (89). In the 
colon, deregulation of Wnt signalling is recognised as the key initiating event in 
colorectal cancer; activation of Wnt/β-catenin signalling, most commonly through 
inactivating mutations in APC, leads to the formation of benign polyps, the first stage 
in the adenoma to carcinoma sequence (90).  Important studies in stem cell biology 
have begun to identify the mechanisms underpinning the expansion of the APC mutant 
stem cells that contribute to the earliest stages of colorectal tumour development (91), 
which may represent novel targets for therapeutic intervention. 
 
Previous data have highlighted the importance of the interplay between NF-κB 
signalling and the Wnt/β-catenin pathway in colorectal carcinogenesis; in particular 
that non-stem cells engineered to exhibit high levels of Wnt and NF-κB signalling can 
de-differentiate, initiating tumours in mice (92). Recently we have shown that BCL-3 is 
an important co-activator of β-catenin/TCF-mediated transcriptional activity in 
colorectal cancer cells, increasing expression of Wnt-regulated intestinal stem cell 
genes. BCL-3 was demonstrated to bind to β-catenin; RNAi-mediated BCL-3 
suppression reduced β-catenin/TCF-dependent transcription and the expression of 
intestinal stem cell genes and Wnt targets LGR5 and ASCL2, both widely accepted 
colorectal cancer stem cell markers (93-97). Furthermore, we showed that BCL-3 
promotes the stem cell phenotype in colorectal cancer cells by increasing colorectal 
spheroid and tumoursphere formation in 3D culture conditions, indicating BCL-3 may 
promote tumour initiation in vivo and may be an effective target for reducing cancer 
stem cell plasticity (33). Results from our study complement findings by Chen et al. 
who suggest BCL-3 promotes stem-like activity and contributes to the maintenance of 
naïve pluripotency in mouse embryonic stem cells (98). Due to it’s role in regulating 
both β-catenin and NF-κB signaling, it is interesting to speculate that BCL-3 may 
enhance the de-differentiation of non-stem cells (92), therefore aiding reconstitution of 
the tumour when the cancer stem cells have been deleted (95).  
 
Conclusion 
BCL-3 may represent an exciting new route for targeting the Hallmarks of Cancer; in 
particular by limiting the impact of the enabling hallmarks of tumour promoting 
inflammation and cell plasticity. Excitingly, targeting stem cell plasticity offers the 
possibility of overcoming some of the limitations of directly targeting CSC highlighted 
in recent studies (95). We suggest that targeting BCL-3 function (through suppressing 
the stem-like potential of cancer cells) would increase the tumour response to 
conventional treatment, reduce the chance of relapse and hence improve the 
prognosis for colorectal cancer patients. Given the emerging role of BCL-3 in a number 
of different cancers, we are hopeful that the new class of BCL-3 inihibtors currently 
under development will prove effective in a wide range of human cancers. 
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Figure legends 
 
Figure 1. Principal components of NF-κB signalling. NF-κB signalling relies on 
three principal proteins: NF-κB proteins, IκB (inhibitor of kappa B) proteins and the IKK 
complex. The five members of the NF-κB family: p65 (RelA), RelB, c-Rel, p50/105 (NF-
κB1) and p50/105 (NF-κB2) all share a N-terminal Rel homology domain (RHD) that is 
responsible for DNA binding and dimerization. RelA, p65 and RelB also have a C-
terminal transcriptional activation domain (TADs) which mediates interactions with 
cofactors but is not present in p50/100 or p52/105. The IκB proteins: IκBα, IκBβ, IκBε, 
BCL-3 and IκBζ are characterised by the presence of multiple ankyrin repeat domains 
(ANK = Red). These domains assemble into elongated cylinders and associate with 
the DNA-binding domains of NF-κB dimers. Classically, IκB proteins sequester NF-κB 
dimers in the cytoplasm rendering them transcriptionally inactive. Atypical IκB proteins 
including BCL-3, the focus of this review, contain additional nuclear localisation signal 
(NLS) and transactivation domains. Unlike typical IκB proteins, these atypical nuclear 
IκB proteins can both inhibit and activate NF-κB target gene expression. The IKK 
complex contains two kinase subunits IKKα and IKKβ and a regulatory subunit NEMO 
(NF-kB essential modifier) or IKKγ. The total number of amino acids in each protein is 
indicated on the right-hand side. Leucin-zipper-like motif (LZ), death domain (DD), 
domain rich in proline (P), glutamate (E), serine (S) and threonine (T) (PEST), Kinase 
domain (Kinase), helix-loop-helix domain (HLH), NEMO-binding domain (NBD), coiled-
coil domain (CC) and zinc-finger domain (Z). Figure created with BioRender.com. 
 
Figure 2. BCL-3 regulation of the atypical NF-κB signalling pathway. The atypical 
pathway is defined as the activation of the NF-κB p50 and p52 homodimers. BCL-3 
acts as a regulator of the atypical NF-κB pathway by binding to processed p50 and 
p52 homodimers to repress or activate a subset of NF-κB regulated genes. In terms of 
transcriptional regulation, BCL-3 stabilizes repressive p50 homodimers bound to κB 
sites by inhibiting ubiquitination and subsequent proteolytic degradation of p50 
homodimers. Additionally, BCL-3 can also recruit co-repressors CtBP and HDAC3 to 
repress transcription of NF-κB target genes. Conversely, BCL-3 directly activates 
transcription of NF-κB target genes by associating with p50 and p52 homodimers, 
providing these homodimers with two transactivation domains that they otherwise lack. 
BCL-3 can also remove repressive p50 homodimers situated at κB sites on DNA, 
allowing NF-κB heterodimers (p65/p50) associated with canonical signalling to activate 
transcription at these sites. Whilst BCL-3 is known to directly interact with p52 
homodimers, the mechanism by which BCL-3 regulates p52 homodimer activation 
remains to be elucidated however it is speculated to follow a similar mechanism to p50 
homodimers. Figure created with BioRender.com. 
 
Figure 3. Gene map of BCL-3 highlighting important sites of post-translational 
modification. BCL-3 is 446 amino acids in length with a proline-rich N-terminus, an 
ankyrin repeat region consisting of 7 ankyrin repeats and a proline and serine rich C-
terminus. In the C-terminus, serine residues S361 and S396 are GSK3 targets and 
result in protein degradation. S33, S114 and S446 are phosphorylated by AKT, ERK2 
and IKK1/2 respectively, leading to stabilisation of BCL-3. Lysine residues K13 and 
K26 undergo ubiquitination with either stabilising K48 or degradative K63 ubiquitin 
chains. Other putative PTM sites in BCL-3 are lysine residue K330 that is thought to 
be monomethylated in resting cells and two potential sites for ATM phosphorylation, 
S361 and S396, both of which are followed by the typical glycine residue found in ATM 
target sites. Figure created with BioRender.com. 
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